IN THE UNITED STATES PATENT AND TRADEMARK

IN RE APPLICATION: James A. RossÉLL, et al.

GROUP ART UNIX Unassigned 0/5498 NA 05 Rec'd PCT/PTO 19 SEP 2005

SERIAL NUMBER: Unassigned

FILED: September 19, 2005

PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF FOR: PATIENT OUTCOME

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir

Applicant(s) wish to disclose the following information.

REFERENCES

- The Applicant(s) wish to make of record the references listed on the attached PTO/SB/08. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
 - A check is attached in the amount required under 37 CFR § 1.17(p).

RELATED CASES

- Attached is a list of applicant's pending applications or issued patents which may be related to the present application. A copy of the patent(s) is attached along with PTO/SB/08.
- A check is attached in the amount required under 37 CFR § 1.17(p).

CERTIFICATION

The undersigned certifies that

- each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- no item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR § 1.56(c) more than three months prior to the filing of this statement.

PETITION

П Applicant(s) hereby request consideration of the attached information. A check is attached in the amount of the Petition fee required under 37 CFR § 1.17(i)(1).

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account No. 50-0911. A duplicate copy of this sheet is enclosed.

> Respectfully submitted, MCKENN&LONG & ALDRIDGE LLP

el Livnat Registration No. 33,949

1900 K Street, N.W. Washington, D.C. 20006 Telephone No: (202) 496-7500

Date: September 19, 2005

PTO/SB/08a/b (05-03)

Approved for use through 05/31/2003. OMB 0631-0031

U.S. Patent and Trademark Officer, U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork	Reduct	ion Aca or 1995, no persons are rea	fulled to respond to a collection of	illionnellori di less il displays a valid Civic coridor rigirilice	
Sul	stitute for form 1449/PTO			Complete if Known		
				Application Number	TBA	
16	VFORMATION	I DI	SCLOSURE	Filing Date	September 19, 2005	
STATEMENT BY APPLICANT				First Named Inventor	James A. RUSSELL, et al.	
				Art Unit =	TBA	
	(use as many sheets as necessary)			Examiner Name ************************************	TBA Pohnert	
heet	1	of	1	Attorney Docket Number	28903.0003	

U.S. PATENT DOCUMENTS					
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
/SP/	AA	US2002/0086838 A1	07-04-2002	Oh et al.	

		FOREI	GN PATENT	DOCUMENTS		_
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
/SP/	BA	WO 98/53098	11-26-1998			

"EXAMINER: Initial if reference considered, whether or not clasion is in conformance with MPEP 606. Draw line through citation if rod in conformance and not considered, include copy of this form with next communication to applicant." Applicants unique clasion designation number (optional). See Nints Codesed (optional conformation in the conformation of the very of the reging of the Emperor must precede the application number of the patient document. Which of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 10 if possible. "Applicant is to place a check mark here if English language Transition is attached.

		NON PATENT LITERATURE DOCUMENTS	
	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T²
/SP/	CA	Raymond L. Benza, M.D., "Association of a Gene Polymorphism for PAI-1 with Primary Pulmonary Hypertension", Cardiopulmonary Critical Care Newsletter, Spring 2002, pages 7-9	
/SP/		Peter W. M. Hermans, et al., "4G/5G Promoter Polymorphism in the Plasminogen-Activator- Inhibitor-1 Gene and Outcome of Meningococcal Disease", Vol. 354, No. 9178, August 14, 1999, pages 556-560	
/SP/		D. R. Ćatchpoole, et al., "The Potential Turnour Suppressor Role for Caspase-9 (CASP9) in the Childhood Malignancy, Neuroblastoma", European Journal of Cancer, Pergamon Press, Oxford, GB, Vol. 37, No. 17, 2001, pages 2217-2221	
/SP/		E. Noguchi, et al., "Identification of Missense Mutation in the IL12B Gene: Lack of Association between IL12B Polymorphisms and Asthma and Allergic Rhinitis in the Japanese Population", Genes and Immunity, Nature Publishing Group, GB, Vol. 2, 2001, pages 401-403	
/SP/		Marie-Christine Gaillard, et al., "Identification of DNA Polymorphisms Associated with the V type Alpha-Antitrypsin Gene", Biochimica et Biophysica Acta, Gene Structure and Expression, Elsevier, Amsterdam, NL, Vol. 1444, No. 2, February 16, 1999, pages 166-170	
/SP/		Sally J. Dawson, et al., "The Two Allele Sequences of a Common Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PA-I) Gene Respond Differently too Interleukin-1 in HepG2 Cells", Journal of Biological Chemistry, Vol. 268, No. 15, 1993, pages 10739-10736.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here If English language Translation is attached.

Examiner	/Steven Pohnert/ (08/27/2009)	Date
Signature	/Steven Ponnert/ (08/27/2009)	Considered
		00.50252880